Vitiligo
☆ AI Dermatology — Free Service
A cikin sakamakon Stiftung Warentest na 2022 daga Jamus, gamsuwar mabukaci tare da ModelDerm ya ɗan yi ƙasa kaɗan fiye da biyan shawarwarin telemedicine.
A cikin sakamakon Stiftung Warentest na 2022 daga Jamus, gamsuwar mabukaci tare da ModelDerm ya ɗan yi ƙasa kaɗan fiye da biyan shawarwarin telemedicine.
Non-segmental vitiligo (Vitiligo mara rabe‑rabe)
Vitiligo a yatsun hannu ya fi wahala a magance fiye da sauran wurare. Baya ga rashin kyawun kamanni, vitiligo cuta ce ta al'ada kuma ba ta yaduwa. A fannin dermatology, maganin da ya fi tasiri shi ne phototherapy ko laser (excimer) sau 2 zuwa 3 a mako, na akalla shekara guda. Idan ba za ku iya zuwa asibiti akai-akai saboda dalilan kuɗi ko aiki, za ku iya amfani da na'urar phototherapy da aka amince da ita don amfani a gida.
Vitiligo a kan hannu
relevance score : -100.0%
ReferencesVitiligo cuta ce ta fata da ta zama gama gari, wacce ke haifar da fararen tabo a fata saboda asarar melanocytes. Binciken baya-bayan nan ya nuna cutar tana da saurin kamuwa da cuta. Duk da yake ana yawan ganin ta a matsayin batun kwaskwarima, zai iya yin tasiri sosai ga lafiyar kwakwalwa da rayuwar yau da kullum. A shekara ta 2011, masana sun ware nau'i mai suna segmental vitiligo daban da sauran.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Marasa lafiya na vitiligo masu aiki suna da zaɓuɓɓukan magani da yawa, kamar su systemic glucocorticoids, phototherapy, da immunosuppressive agents. Marasa lafiya da vitiligo mara ƙarfi na iya amfana daga topical corticosteroids, topical calcineurin inhibitors, phototherapy, da hanyoyin dasawa. Sabbin ci gaban fahimtar hanyoyin vitiligo sun haifar da ƙarin hanyoyin magani. A halin yanzu, JAK inhibitors sune mafi alƙawari, suna ba da haƙuri mai kyau da sakamako mai tasiri, duk da haɗarin ƙara yaduwar cututtuka masu ɓoye da kuma tasirin tsarin da ke tattare da wasu wakilai na rigakafi. Ci gaba da bincike na nufin gano mahimman cytokines da ke cikin haɓakar vitiligo (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF). Kashe waɗannan cytokines ya nuna alƙawari a cikin ƙirar dabba da wasu marasa lafiya. Bugu da ƙari, ana gudanar da bincike kan miRNA‑based therapeutics da adoptive Treg cell therapy.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Ba a san maganin vitiligo ba. Ga waɗanda ke da fata mai haske, maganin rana da kayan shafa su ne abubuwan da aka saba ba da shawara. Sauran zaɓuɓɓukan magani na iya haɗawa da kirim na steroid ko phototherapy.
○ Magani
#Phototherapy
#Excimer laser
#Tacrolimus ointment